Table 1.
Characteristics of studies including nivolumab-plus-ipilimumab and nivolumab therapy
| Characteristics | Wolchok et al28 (2017) | Hassel et al29 (2017) | Hellman et al27 (2018) | Antonia et al26 (2016) |
|---|---|---|---|---|
|
| ||||
| Designation | Check Mate 067 | Check Mate-037, -066 and -067 | Check Mate 227 | Check Mate 032 |
| Histology | Melanoma | Melanoma | NSCLC | SCLC |
| Design | Phase III RCT | Phase III RCT | Phase III RCT | Phase I/II trial, open-label |
| Patients (N/N+I) | 313/313 | 787/407 | 391/576 | 98/61 |
| Monotherapy | Nivolumab | Nivolumab | Nivolumab | Nivolumab |
| 3 mg/kg q2w | 3 mg/kg q2w | 3 mg/kg q2w | 3 mg/kg q2w | |
| Combine therapy | Nivolumab (1 mg/kg q2w) | Nivolumab (1 mg/kg q2w) | Nivolumab (3 mg/kg q2w) | Nivolumab (1 mg/kg q2w) |
| plus ipilimumab (3 mg/kg q6w) | plus ipilimumab (3 mg/kg q6w) | plus ipilimumab (1 mg/kg q6w) | plus ipilimumab (3 mg/kg q6w) | |
| Jaded score | 5 | 5 | 5 | 3 |
Abbreviations: NSCLC, non-small-cell lung cancer; RCT, randomized controlled trial; SCLC, small-cell lung cancer; q2w, every 2 weeks; q6w, every 6 weeks.